Podcast appearances and mentions of stephen archer

Eoin Sheahan is joined by Richie McCormack and Cameron Hill as Ireland have been dealt another blow to their World Cup hopes as Dorothy Wall has been ruled out with an Achilles strain, while Stephen Archer announces his retirement. They also bring you team news from the UEFA Champions League semi final between Barcelona and Inter.

Preview also available on our YouTube channel Our guest : NEIL “KEEGO” KEEGAN https://twitter.com/keegolaughs_irl www.keegolaughs.com Apologies Up Front on Apple Podcasts LEINSTER : 15. Hugo Keenan 14. Liam Turner 13. Garry Ringrose 12. Jamie Osborne 11. James Lowe 10. Ciarán Frawley 9. Jamison Gibson-Park 1. Andrew Porter 2. Lee Barron 3. Tadhg Furlong 4. RG Snyman 5. James Ryan 6. Jack Conan 7. Josh van der Flier 8. Caelan Doris (c)  16. Gus McCarthy 17. Cian Healy 18. Thomas Clarkson 19. Ryan Baird 20. Max Deegan 21. Luke McGrath 22. Ross Byrne 23. Harry Byrne Munster : 15 Mike Haley; 14 Calvin Nash, 13 Tom Farrell, 12 Alex Nankivell, 11 Seán O'Brien; 10 Jack Crowley, 9 Craig Casey 1 Jeremy Loughman, 2 Niall Scannell, 3 Stephen Archer; 4 Jean Kleyn, 5 Tadhg Beirne (C); 6 Jack O'Donoghue, 7 John Hodnett, 8 Gavin Coombes. 16 Diarmuid Barron, 17 Kieran Ryan, 18 John Ryan, 19 Tom Ahern, 20 Ruadhán Quinn, 21 Conor Murray, 22 Tony Butler, 23 Shay McCarthy. United Rugby Championship 24/25 Round 4 Saturday, October 12, 2024 KO 5:45pm Stadio Monigo Live on: RTÉ2, Premier Sports 1, & URC.tv Referee: Chris Busby (IRFU) AR 1: Peter Martin (IRFU) AR 2: Keane Davison (IRFU) TMO: Mark Patton (IRFU) Where to find Harpin' On Rugby https://linktr.ee/harpinonrugby COMMENT/SHARE/FOLLOW/SUBSCRIBE

Send us a Text Message.In this episode we celebrate the Archer's...a family of aviators. 89-year-old Pan Am Captain Stu Archer joined the airline in 1965 as an engineer after serving in the U.S. Air Force. Stu began flying the 727 and then was promoted to captain on the 747 and later Airbus A300 and A310. He stayed with Pan Am until 1991 and then went on to work for Delta Air Lines as a captain. When he reached the then mandatory retirement age of 60 after three years as a Delta captain, he successful took the company to court forcing the airline to keep him as an engineer and worked for another seven years before retiring in 2000. Many credit his lawsuit as one of the reasons the mandatory age was raised to 65. Stu credits his uncle, Lawerence Archer, as his aviation inspiration. Born in 1903, Lawerence was one of the early pilots trained by the Wright Brothers and was the first person to deliver mail by air in New England. Uncle Lawerence took Stu on his very first flight in a single engine, open air cockpit bi-wing plane when he was six years old and this forever changed the trajectory of his life. Lawerence Archer gave his life in service to his country in 1945 during World War II serving in the U.S. Army Air Corps. Stu's daughter Deborah Archer joined Pan Am as a flight attendant in 1979 and worked for the airline until the end in 1991. Afterward, she hung up her wing and became a nurse. She sadly passed away in 2009. Stu's son, Captain Jeffery Archer followed in his father's footsteps and became a pilot for American Airlines in 1991 and became captain in 1995. And now his grandson, Stephen Archer, Jeffery's son, carries on the family legacy started by his great-uncle and was recently been promoted to Captain with Envoy Air, a subsidiary of American Airlines. All three of these captains will be joining us to talk about their passion for flying and careers in aviation.A special thank you to American Airlines for allowing Jeff and Stephen to participate in this interview. If you are thinking about starting a career in aviation and want to be a pilot for American Airlines, visit the AA Cadet Academy. The Pan Am Museum also encourages you to visit the American Airlines CR Smith Museum in the Dallas/Fort Worth area. This museum is named after aviation pioneer and former President of American Airlines, Cyrus Rowlett Smith and has been open since 1993.  Support the Show. Visit Us for more Pan Am History! Support the Podcast! Donate to the Museum! Visit The Hangar online store for Pan Am gear! Become a Member! Follow us on Facebook, Instagram, and Twitter!A very special thanks to Mr. Adam Aron, Chairman and CEO of AMC and president of the Pan Am Historical Foundation and Pan Am Brands for their continued and unwavering support!

Sunday 7th April, Morning Service: Listen to this morning's message on John 21:1-19 from Stephen Archer, entitled 'A Second Chance'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

All families have squabbles from time to time - it's human nature. But sometimes, a squabble exists only in the mind of one family member, and when they become obsessed that they are right, wild horses cannot change their mind - sometimes, it borders on paranoia. The tale this time around on The True Crime Enthusiast Podcast, a horrific tale from Manchester back in 2016, shows just what horrific consequenses paranoia can bring.  The episode contains details and descriptions of crimes and events, involving  descriptions of injury detail, that some listeners may find disturbing and or distressing, so discretion is advised whilst listening. Music used in this episode: "The Descent" by Kevin Macleod. All music used is sourced from https://filmmusic.io/ and used under an Attribution Licence (https://creativecommons.org/licenses/by/4.0/) Show Sponsor - Surfshark - Enjoy the ultimate privacy protection service with the best VPN. Get 3 months FREE HERE Playlist Tracks Jethro Tull - Thick As A Brick SUUNS - Images du futur The True Crime Enthusiast's Fundraiser For Macmillan Cancer Support References Killer who burned his sister to death is jailed for life - Manchester Evening News Stephen Archer found guilty of murdering sister with a petrol bomb after he was left out of father's will - Manchester Evening News Man denies petrol bomb murder of sister and says he would have stabbed her if he wanted to kill her - Manchester Evening News Who is Stephen Archer? Murderer who killed his sister Julie with homemade petrol bomb | The Sun Manchester man who burnt sister alive jailed for 27 years | Daily Mail Online Stephen Archer gets life for sister's petrol bomb murder - BBC News Stephen Archer guilty of sister's petrol bomb murder - BBC News Woman fire attack: Brother held on suspicion of murder - BBC News Sister fire attack: Petrol stations warned in hunt for brother - BBC News Hunt for brother over burned woman - BBC News Manhunt launched in Manchester after woman set on fire - BBC News Petrol bomb murderer Stephen Archer maintains sister's killing was 'horrific freak accident' in letter - Manchester Evening News Man who denies petrol bomb murder of his sister says 'I'd stab her if I meant to kill' - Mirror Online Man doused his sister in petrol and set her on fire   | STV News Archive Man goes on trial accused of burning his sister to death | ITV News Granada Man who burned sister alive with homemade petrol bomb jailed for 27 years | UK News | Metro News (18) Judge Rinder Crime Stories Series 3 Episode 1 - YouTube Manchester man burned sister alive with 'petrol cocktail' after being left out of father's will | IBTimes UK Manchester police hunt Stephen Archer after woman is doused in petrol in Newton Heath | IBTimes UK Manchester: Mother burnt alive in petrol bomb attack got her 'karma' brother gloated, court hears | IBTimes UK UK: Man charged with murder after woman is doused in petrol | IBTimes UK Man who killed sister by dousing her in petrol and setting her alight gets life sentence (thejournal.ie) Manchester man 'murdered his sister with Pepsi cola bomb' | Daily Mail Online Mum who died from 'horrific injuries' after being 'set on fire by brother' tried to rescue trapped daughter - Irish Mirror Online Woman died from 95% burns after brother 'doused her in petrol from Pepsi bottle and set her alight' - Mirror Online Petrol bomb murderer who turned sister into human fireball in row over dad's will jailed for life - Mirror Online Life behind bars for man who set his sister on fire in Newton Heath. | News - Hits Radio (Manchester) (planetradio.co.uk) Stephen Archer's mother made appeal to son before police found him | Daily Mail Online Man sought over petrol attack on woman sent mother birthday card | UK news | The Guardian Police hunt 'dangerous and unstable' fugitive who doused woman with petrol and set her alight in Manchester | The Independent | The Independent Evil brother who burnt his sister alive with homemade petrol bomb after he was cut out of his dad's will is jailed for life | The Sun Criminal sentence - Stephen Archer - Manchester Crown Court - Mr Justice Openshaw (thelawpages.com) Bloke gets 27 years for petrol bomb murder of sister after blaming her for dad's death - Daily Star Woman died from 95% burns after brother 'doused her in petrol from Pepsi bottle and set her alight' - Irish Mirror Online Grieving children pay tribute to tragic mum Julie Archer - Manchester Evening News Crowdfunding to for the family & burns unit at wythenshawe hospital ❤️ on JustGiving Childhood friend pays tribute to tragic Julie Archer - Manchester Evening News Manchester man who burnt sister alive jailed for 27 years | Daily Mail Online Police launch manhunt after 'burning woman' left fighting for life following horror fire at Newton Heath home - Manchester Evening News Follow/Contact/Support The True Crime Enthusiast Podcast Facebook Facebook Discussion Group Twitter Instagram Youtube Website TTCE Merchandise Patreon Page Remembering Julie, and her family. This episode is dedicated to them. 

Sunday 18th February, Evening Service: Listen to the message on Luke 15:1-10 from Stephen Archer, entitled 'Love For Lost Things'. This forms Part 62 of our series on Luke's Gospel, 'Gospel Certainty'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 7th January, Evening Service: Listen to this evening's message from Stephen Archer on Genesis 9:8-17, and the theme of our Church Motto for 2024, entitled 'Holding Fast To Our Hope'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Preview also available on our YouTube channel Leinster : 15. Hugo Keenan 14. Jordan Larmour 13. Garry Ringrose (CAPTAIN) 12. Ciarán Frawley 11. Rob Russell 10. Harry Byrne 9. Jamison Gibson-Park 1. Andrew Porter 2. Rónan Kelleher 3. Michael Ala'alatoa 4. Ross Molony 5. Joe McCarthy 6. Max Deegan 7. Scott Penny 8. Jack Conan 16. Dan Sheehan 17. Ed Byrne 18. Thomas Clarkson 19. Jason Jenkins 20. Ryan Baird 21. Luke McGrath 22. Liam Turner 23. Will Connors Munster : 15 Simon Zebo; 14 Calvin Nash, 13 Antoine Frisch, 12 Alex Nankivell, 11 Shane Daly; 10 Jack Crowley, 9 Craig Casey; 1 Dave Kilcoyne, 2 Diarmuid Barron (C), 3 Oli Jager; 4 Edwin Edogbo, 5 Gavin Coombes; 6 Tom Ahern, 7 John Hodnett, 8 Jack O'Donoghue. 16Eoghan Clarke, 17 Jeremy Loughman, 18 Stephen Archer, 19 Brian Gleeson, 20 Alex Kendellen, 21 Paddy Patterson, 22 Tony Butler, 23 Seán O'Brien. BKT United Rugby Championship 23/24 Round 8 Tuesday, December 26, 2023 KO 7:35pm Thomond Park TV : TNT Sports 1 Live on: RTÉ2, Premier Sports 1, URC.tv Referee: Andrew Brace (IRFU, 91st league game) AR 1: Peter Martin (IRFU) AR 2: Andrew Cole (IRFU) TMO: Brian McNeice (IRFU) JAY LONG https://twitter.com/Jay_Long_626 Where to find Harpin' On Rugby Website > https://harpinonrugby.com/ BlueSky > https://bsky.app/profile/harpinonrugby.bsky.social Twitter > https://twitter.com/HarpinOnRugby Facebook > https://www.facebook.com/HarpinOnRugby Instagram > https://www.instagram.com/harpinonrugby/ TikTok > https://www.tiktok.com/@harpinonrugby YouTube > https://youtube.com/@HarpinPreviewShow COMMENT/SHARE/FOLLOW/SUBSCRIBE --- Send in a voice message: https://podcasters.spotify.com/pod/show/harpinonrugby/message

Sunday 17th December, Morning Service: Listen to this morning's message on Luke 1:46-56 from Stephen Archer, entitled 'The Song Of Mary'. This forms Part 3 of our 'Speaking Of Christmas' series. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 3rd December, Evening Service: Listen to this evening's message on Psalm 134 from Stephen Archer, entitled 'Blessed Ministry'. This forms Part 15 of our 'Songs For The Road' series. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Ruairi O'Hagan is joined by Munster legends Alan Quinlan and Fiona Hayes to look back on the Reds' defeat to Leinster and the positive aspects of the performance. Fiona and Alan pick their Star of the Week, there's a preview of the clash with table toppers Glasgow in Cork, we talk about new deals for Munster stars and we discuss Peter O'Mahony standing down as captain.(0.30) Intro (5.00) Review of Leinster v Munster(21.45) Star of the Week (26.17) Glasgow Warriors Preview(40.00) Stephen Archer becomes Munster's most capped player(43.00) New Contracts, RG Snyman's departure confirmed(47.00) Peter O'Mahony stands down as skipperGet in contact on Twitter @rugbychannel15 or email therugbychannel@bauermedia.ieSubscribe to The Rugby Channel for new episodes every week! #TheRed78The first twenty minutes of this week's podcast is unlocked, but to listen to the full podcast, get on over to the Off The Ball app, or become a member at offtheball.com/join.

Ruairi O'Hagan is joined by Munster legends Alan Quinlan and Fiona Hayes to look back on the Reds' defeat to Leinster and the positive aspects of the performance. Fiona and Alan pick their Star of the Week, there's a preview of the clash with table toppers Glasgow in Cork, we talk about new deals for Munster stars and we discuss Peter O'Mahony standing down as captain.(0.30) Intro (5.00) Review of Leinster v Munster(21.45) Star of the Week (26.17) Glasgow Warriors Preview(40.00) Stephen Archer becomes Munster's most capped player(43.00) New Contracts, RG Snyman's departure confirmed(47.00) Peter O'Mahony stands down as skipperGet in contact on Twitter @rugbychannel15 or email therugbychannel@bauermedia.ieSubscribe to The Rugby Channel for new episodes every week! #TheRed78The first twenty minutes of this week's podcast is unlocked, but to listen to the full podcast, get on over to the Off The Ball app, or become a member at offtheball.com/join.

Preview also available on our YouTube channel Leinster : 15. Hugo Keenan 14. Jordan Larmour 13. Garry Ringrose (cc) 12. Robbie Henshaw 11. Jimmy O'Brien 10. Ross Byrne 9. Jamison Gibson-Park 1. Andrew Porter 2. Dan Sheehan 3. Tadhg Furlong 4. Joe McCarthy 5. James Ryan (cc) 6. Jack Conan 7. Josh van der Flier 8. Caelan Doris 16. Rónan Kelleher 17. Jack Boyle 18. Michael Ala'alatoa 19. Ross Molony 20. James Culhane 21. Ben Murphy 22. Ciarán Frawley 23. Scott Penny Munster : 15 Simon Zebo; 14 Calvin Nash, 13 Antoine Frisch, 12 Rory Scannell, 11 Shane Daly; 10 Jack Crowley, 9 Craig Casey 1 Jeremy Loughman, 2 Diarmuid Barron (C), 3 Stephen Archer; 4 Jean Kleyn, 5 Tadhg Beirne; 6 Tom Ahern, 7 John Hodnett, 8 Gavin Coombes. 16 Scott Buckley, 17 Dave Kilcoyne, 18 John Ryan, 19 Brian Gleeson, 20 Alex Kendellen, 21 Conor Murray, 22 Tony Butler, 23 Shay McCarthy. (Check the previous pod for an Opposition View from Munster fan Caolán Scully) United Rugby Championship 23/24 Round 6 Saturday, November 25, 2023 KO 6:30pm Aviva Stadium TV : TG4, Premier Sports 1, URC.tv Referee: Chris Busby (IRFU) AR 1: Peter Martin (IRFU) AR 2: Keane Davison (IRFU) TMO: Mark Patton (IRFU) Our guest JAY LONG https://twitter.com/Jay_Long_626 Where to find Harpin' On Rugby Website > https://harpinonrugby.com/ Mastodon > @HarpinOnRugby@mastodon.ie Twitter > https://twitter.com/HarpinOnRugby Facebook > https://www.facebook.com/HarpinOnRugby Instagram > https://www.instagram.com/harpinonrugby/ TikTok > https://www.tiktok.com/@harpinonrugby YouTube > https://youtube.com/@HarpinPreviewShow COMMENT/SHARE/FOLLOW/SUBSCRIBE --- Send in a voice message: https://podcasters.spotify.com/pod/show/harpinonrugby/message

Sunday 8th October, Morning Service: Listen to this morning's message on Ephesians 5:22-33 from Stephen Archer, entitled 'How Does God View The Church?'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 3rd September, Morning Service: Listen to this morning's message on Hebrews 13 from Stephen Archer, entitled 'Trusting In An Unchanging Saviour'. This forms Part 6 of our 'Highlights From Hebrews' series. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 2nd July, Morning Service: Listen to this morning's message on Psalm 46 from Stephen Archer, entitled 'Rest In A Chaotic World'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 2nd July, Evening Service: Listen to this evening's message on 1 Corinthians 1:18-2:5 from Stephen Archer, entitled 'The Cross: God's Wise Stupidity'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 21st May, Morning Service: Listen to the message on Nehemiah 12:22-47 from Stephen Archer, entitled 'Renewed Worship'. This forms Part 13 of our series of studies in the book of Nehemiah, 'Rubble and Renewal'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Kevin is a Senior Research Associate at Bigelow Laboratory for Ocean Sciences, where he works in the air-sea exchange laboratory with Dr. Stephen Archer in the biogeochemistry wing of Bigelow Laboratory. The general focus of the laboratory is to understand the sources and controls of atmospherically active gases produced by marine microorganisms. This work helps build a cross-scale understanding of the impacts/feedbacks of climate change, particularly ocean acidification, on critical biogeochemical cycles. Kevin is also part of the team researching how seaweed may be able to help reduce carbon emissions from cows. Kevin was a speaker at the 2022 Maine Science Festival 5 Minute Genius(TM) event. Our conversation was recorded in January 2023.~~~~~~The Maine Science Podcast is a production of the Maine Science Festival and Maine Discovery Museum. It was recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle.The Discover Maine theme was composed and performed by Nick Parker.If you want to support the Maine Science Podcast and/or the Maine Science Festival, you can do so at our website mainesciencefestival.org at our donation page. Find us online:Website - Maine Science FestivalMaine Science Festival on social media: Facebook    Twitter     InstagramMaine Science Podcast on social media: Facebook    Twitter     Instagram© 2023 Maine Science FestivalA program of the Maine Discovery Museum 

Stephen Archer, and Other Tales

Sunday 2nd April, Morning Service: Listen to this morning's message on Mark 11:1-11 from Stephen Archer, entitled 'God's Surprising Triumph'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 26th February, Morning Service: Listen to the message on Nehemiah 3 from Stephen Archer, entitled 'Renewed Participation'. This forms Part 4 of our series of studies in the book of Nehemiah, 'Rubble and Renewal'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

During the COVID 19 vaccine rollout Canadians learned the hard way that they're at the mercy of other countries to get the shot. In the past, Canada manufactured vaccines but that was decades ago. Can Canadian innovations in science rest on the laurels of the discovery of insulin and its long-ago foray into vaccines? Or should it strive to become a global leader in scientific discoveries? We ask physician scientist Stephen Archer; Support Our Science co-organizer Sarah Laframboise; and Globe and Mail science reporter Ivan Semeniuk.See omnystudio.com/listener for privacy information.

This interview is with Stephen Archer of Hard Air Magazine at the 2022 Extreme Benchrest XI. You can find Stephen Archer's magazine here: https://hardairmagazine.com/ For information about Extreme Benchrest check here: www.extremebenchrest.com For information about Airguns of Arizona go here: www.airgunsofarizona.com Make sure to subscribe to the YouTube channel @Atlas Airguns Official Atlas Airguns Podcast link Atlas Airguns Instagram Atlas Airguns Twitter Have a question? Email atlasairguns@gmail.com --- Support this podcast: https://anchor.fm/atlas-airguns/support

Sunday 27th November, Morning Service: Listen to this morning's message on Revelation 21 from Stephen Archer, entitled 'All Things New'. This forms Part 23 of our 'Blessed Endurance' series of studies in the Revelation of Jesus Christ. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Jeyan Jeganathan talks to Queen's University professors Dr. Stephen Archer and Dr. Gerald Evans about new research into how SARS-CoV-2 worsens COVID-19 pneumonia.See omnystudio.com/listener for privacy information.

Sunday 30th October, Morning Service: Listen to this morning's message on 2 Corinthians 5:11-21 from Stephen Archer, entitled 'Motivation For Ministry'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 9th October, Morning Service: Listen to the message from Stephen Archer, entitled 'Getting The Gospel Right: Conversion'. This forms Part 1 of our short series, 'Gospel People: Knowing and Sharing Our Faith'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Sunday 25th September, Evening Service: Listen to the message on Philippians 1:27-30 from Stephen Archer, entitled 'The Battlefield'. This forms Part 2 of our short series on Philippians, 'Shared Joy'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube. Video of entire service available on our YouTube Channel.

Wednesday 17th August, Midweek Service: Listen to this evening's message from Stephen Archer, entitled 'Rahab: A Positive Example'. Visit us online at portadownbaptist.com - or follow us on Facebook, Twitter or YouTube.

For months (in fact years now) we've been using hand sanitizers, masking up, and socially distancing.  However, in the middle of all of that germ dodging, could we have overlooked the biggest germ carrier? You know it... it's your phone.  You can get UV sanitizers for your phone, and they even come with an aromatherapy function too, but what do we need to know about the device that seldom leaves our side?  Dr Stephen Archer is a microbiologist with the answers to this rather grim question...See omnystudio.com/listener for privacy information.

Hear from Munster Head Coach Johann van Graan and Stephen Archer ahead of Friday night's URC clash against Ulster in Belfast.

Munster Rugby Senior Coach Stephen Larkham and the squad's most-capped player Stephen Archer spoke to the media this week ahead of Sunday's Champions Cup clash against Wasps at Thomond Park.

A Freedom of Information Act (FOIA) request revealed that Dr Fauci and Director Collins conspired to silence and discredit any science and scientists who spoke against their Public Health measures, specifically focussing on and targeting the Great Barrington Declaration. Authored and signed by leading Scientists and Epidemiologists from Stanford, Harvard, Oxford and Yale - along with 60,000 of the worlds leading subject matter experts.What's most concerning however, is Stephen Archer, Professor, Head of the Department of Medicine at Queens University here in Canada, parroted their message, a few mere weeks after Director Collins and Dr Fauci agreed to execute their hit piece against contradictory science. Needless to say, the scientific method does not allow for attacking dissenting opinions. What's most alarming however, is the flagrant politicization of science by one of the most prominent Medical Professionals our country has to offer.Its time Stephen Archer withdraws his condemnation against the Great Barrington Declaration and admits that the public health measures designed to stop community spread in order to protect the vulnerable, beneath a mountain of evidence, proved to be ineffective and harmful. It is time Canada moves on from this draconian Public Health experiment and its abject failure acknowledged by those who implemented it.Podcast available on all of your favourite podcast platforms (iTunes, Google Play, Spotify, etc). You can also listen to the podcast in your browser directly from the CH1.ca platformPodcast NotesCIDRAP Masks - https://www.cidrap.umn.edu/news-perspective/2020/04/commentary-masks-all-covid-19-not-based-sound-dataNational Post Now wear masks that work - https://nationalpost.com/health/with-omicron-cases-surging-its-time-to-ditch-the-cloth-mask-experts-say400 papers demonstrating zero effectiveness with respect to our public health measures - https://brownstone.org/articles/more-than-400-studies-on-the-failure-of-compulsory-covid-interventions/How Fauci and Collins Shut Down Covid Debate - They worked with the media to trash the Great Barrington Declaration - https://www.wsj.com/articles/fauci-collins-emails-great-barrington-declaration-covid-pandemic-lockdown-11640129116Stephen Archer, Head of Department of Medicine Queens University Canada - https://www.queensu.ca/gazette/stories/5-failings-great-barrington-declaration This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit andrewrouchotas.substack.com

Panellists Nicky Pellegrino and Conor English discuss BNZs lending limits, the opposition to the All Blacks being sponsored by an oil, gas and plastics company, and dirty pillows. Participants: Sir Bob Harvey, Glen McLeod, Stephen Archer

In this episode, let's listen to Stephen Archer, the Strategic Partner Liaison at Impresiv Health. Stephen shares how Impresive is dedicated to improving operations management standards by offering a suite of solutions that have been proven efficient. He talks of providing consulting services at a fair market value through niche-focused expertise, designing services around things that other companies don't do as well, and insights on project support. If you're looking to improve the quality of care for your patients or want to work with payor companies and providers, this is a podcast interview for you! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Suzanne Lynn is joined this week by authors TaNesha McAuley, "Not Your Average Jo;" Stephen Archer, "Searchers: The Irish Clans;" Rowald Holt, "1870-2020: History Debunked;" Gail Koger, "Shenanigans;" and Samuel L. Charles, "Gemnist Goes to Brooklyn."

In this special episode we launch our interview series by talking with Stephen Archer, a Mindfulness Educator with over 40 years of experience. We get into the neuroscience behind mindfulness, misconceptions about mindfulness, starting a practice in daily life and we also talk about how chasing after happiness could be chasing after the wrong thing! About Stephen: www.mwfo.co.nz  Stephen Archer is Managing Director and lead trainer and supervisor for Mindfulness Works For Organisations. Stephen has been involved with mindfulness for 40 years and began practicing while he was finishing a degree in Eastern studies in the UK. At the age of 23 Stephen was formally trained in mindfulness as an ordained Buddhist monk in the Thai forest tradition. His training included working closely with different teachers and completing lengthy retreats to strengthen his practice. Thirteen years later he emerged from the monkhood with the intention to offer his skills and learnings to the public. During the last 25 years Stephen has run workplace mindfulness trainings for organisations including Westpac, Kiwibank, Air New Zealand and NZ Police, delivered courses in healthcare and prisons, and assisted the Mental Health Foundation of NZ to develop their approach to mindfulness. He has worked at the Leadership Development Centre in Wellington running year-long mindful leadership programmes, and is also a trustee of Te Moata, a retreat centre and nature sanctuary in the Coromandel. Like and follow us on:  Facebook: https://www.facebook.com/Confuddled/ Twitter: @Confuddled_Pod  Instagram: confuddled_podcast YouTube: https://www.youtube.com/channel/UCBXKCnESJerucIRWP6Ib6Sg Intro/Outro:  Music by Michaela Cornelius (https://soundcloud.com/mikatte). Voice by Erin O'Flaherty (https://erinoflaherty9.wixsite.com/performerwriter)  

In this episode, let's listen to Stephen Archer, the Strategic Partner Liaison at Impresiv Health. Stephen shares how Impresive is dedicated to improving operations management standards by offering a suite of solutions that have been proven efficient. He talks of providing consulting services at a fair market value through niche-focused expertise, designing services around things that other companies don't do as well, and insights on project support. If you're looking to improve the quality of care for your patients or want to work with payor companies and providers, this is a podcast interview for you! https://outcomesrocket.health/impresiv/2020/10/

Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center in Duke National University of Singapore. Dr Greg Hundley: I'm Greg Hundley, associated editor from the VCU Pauley Heart Center in Richmond, Virginia. Dr Carolyn Lam: Greg, today's speaker paper is really special on a number of levels. First, it's a research letter and secondly, it's actually basic science. Now, this tells you it's got to be really special. Well, I'll just give you a hint. It talks about a new therapy for stroke. I'm going to leave it at that, leave you guessing because you've got to hang on as we tell you about the rest of the issue and then listen to the feature discussion. Now, the first original paper here, I want to describe as a basic paper focusing on PDE4B in heart failure. Dr Greg Hundley: All right, Carolyn, I'm not even going to let you start to quiz me on this. Can you tell me what in the world is PDE4B? Dr Carolyn Lam: All right. Phosphodiesterases, or PDEs, really represent a highly diverse super family of enzymes among which PDE3 and PDE4 are the main phosphodiesterases that degrading cyclic AMP with a high affinity in the heart. The cyclic AMP hydrolyzing phosphodiesterase 4B, which is PDE4B, is the key negative regulator of cardiac beta-adrenergic receptor stimulation. PDE4B deficiency leads to abnormal calcium handling and PDE4B is decreased in pressure overload hypertrophy suggesting that increasing PDE4B in the heart may be beneficial in heart failure. These authors led by Dr Vandecasteele from Inserm tested this hypothesis in elegant experiments involving both human cardiac tissues and transgenic mouse lines. Dr Greg Hundley: Carolyn, that was just a wonderful explanation and I really learned about these phosphodiesterases. Now, tell me what did they find in their study? Dr Carolyn Lam: The cyclic AMP hydrolyzing enzyme, PDE4B, was decreased in human failing hearts. Cardiac over expression of PDE4B in mice, resulting in a 15-fold increase in cyclic AMP hydrolysis decreased cardiac contraction and protected against the cardiotoxic effects of chronic beta-adrenergic stimulation. Whereas transgenic mice with a 50-fold increase in cardiac cyclic AMP hydrolysis underwent maladaptive remodeling. Furthermore, cardiac PDE4B gene transfer with serotype nine adeno associated viruses resulted in a significantly lower increase in cardiac PDE4B and protected against chronic catecholamine stimulation and transaortic constriction without depressing basal cardiac function. These results overall suggest that a moderate increase in cardiac PDE4B is beneficial to counteract the detrimental effects of excessive sympathetic system activation in heart failure and increase in PDE4B in the human heart could be achieved by gene therapy with adeno associated viruses or by using recently developed small molecules with PDE4 activating properties. Dr Greg Hundley: Wow, Carolyn. Very interesting. I mean, perhaps this'll work its way into heart failure management. Well, my study, our first study to describe involves the comparative efficacy and safety of oral P2Y12 inhibitors and acute coronary syndromes. It's a meta-analysis of 52,816 patients from 12 randomized trials. It comes to us from Professor Eliano Navarese from Nicholas Copernicus University. All right, Carolyn, here's your quiz. Have you wondered which PGY inhibitor is optimal for reducing risk of adverse cardiovascular events? Dr Carolyn Lam: Oh, that's an easy one. Of course I've wondered, but you're going to tell us the results. Dr Greg Hundley: It's getting harder and harder to trip you up Carolyn. Very clever, okay. This study aims to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor and clopidogrel in acute coronary syndrome by meta-analysis of 12 randomized clinical trials. Again, involving those 52,816 patients with ACS.  Dr Carolyn Lam: Wow. What did they find Greg? Dr Greg Hundley: Compared clopidogrel, ticagrelor significantly reduced cardiovascular mortality and all-cause mortality. Whereas there was no statistically significant mortality reduction with prasugrel. Dr Greg Hundley: Next, compared with each other there were no significant differences in mortality with prasugrel versus ticagrelor. In addition, compared with clopidogrel, prasugrel reduced myocardial infarction, whereas ticagrelor showed no risk reduction. Dr Greg Hundley: Now stint thrombosis risk was significantly reduced by both ticagrelor and prasugrel versus clopidogrel. Compared with clopidogrel, both prasugrel and ticagrelor significantly increased major bleeding. There was no significant difference between prasugrel and ticagrelor for all outcomes explored.  Dr Carolyn Lam: Summarize that for us. Dr Greg Hundley: Okay Carolyn. Prasugrel and ticagrelor reduced ischemic events, but increased bleeding in comparison to clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. So a really nice summary evaluating these P2Y12 inhibitors, Dr Carolyn Lam: Indeed. Question for you, Greg, what is the prevalence of deep venous thrombosis, a DVT and its risk factors, prognosis and potential prophylaxis strategies for hospitalized patients with COVID-19? That's what the next paper is about. It is a single center observational study of 143 hospitalized patients confirmed of COVID-19. And this is from co-corresponding authors, Doctors Xi and Hu from Union Hospital in Wuhan China, Dr Zhang from Beijing Chaoyang, and Dr Ge from St. Christopher Hospital for Children in Philadelphia, United States, they found that DVT was found in a high percentage of these patients. Forty-six percent of the 143 patients and was associated with adverse outcomes with CURB-65 score three to five. Padua prediction score four a more and D-dimer greater than one microgram per mil, which in combination predicted DVT with a sensitivity of more than 88.5%. Thrombo prophylaxis was associated with lower DVT in a subgroup of patients with high Padua prediction score. Dr Greg Hundley: Now, what does this mean for all of us in this era of COVID-19? Dr Carolyn Lam: So this suggests that DVT is more common in hospitalized patients with COVID-19. So ultrasound screening of high-risk patients, as I mentioned before, may be indicated for the more prevention of DVT with low molecular weight heparins in high risk patients, such as those with a high Padua prediction scores may reduce DVT in hospitalized patients with COVID-19. Of course more work needs to be done, but a very interesting paper. Dr Greg Hundley: What a fantastic description. Well, my next paper is more from the world of basic science and involves phosphodiesterase 3A in arterial hypertension and comes to us from Dr Enno Klussmann from the Max Delbruck Center for Molecular Medicine. So Carolyn, autosomal dominant hypertension with brachydactyly clinically resembles salt resistant, essential hypertension and causes death by stroke before the age of 50 years. So in this study, the authors use genetic mapping, sequencing, transgenic technology, CRISPR-CAS based nine gene editing, immunoblotting, and fluorescence resonance energy transfer to identify new patients perform extensive animal phenotyping and explore new signaling pathways related to hypertension with brachydactyly.  Dr Carolyn Lam: Wow. So what did they find, Greg? Dr Greg Hundley: Well, Carolyn, the authors described a novel mutation within a 15 BP region of the PDE3A gene, and define this segment as a mutational hotspot in hypertension with brachydactyly, the mutations cause an increase in enzyme activity, a CRISPR-Cas9 generated rat model with a nine BP deletion within the hotspot analogous to human deletion recapitulated the hypertension with brachydactyly in mice, mutant, transgenic PDE3A over expression and smooth muscle cells confirmed that mutant PDE3A caused hypertension. The afferent signaling found in these models was associated with an increase in vascular smooth muscle cell proliferation and changes in vessel morphology and function.  Dr Carolyn Lam: Gosh, so what are the clinical implications? Greg? Dr Greg Hundley: The mutated PDE3A gene drives mechanisms that increase peripheral vascular resistance and cause hypertension. These authors presented two new animal models that serve to elucidate these underlying mechanisms further, and their findings could facilitate the search for new anti-hypertensive treatments. Dr Carolyn Lam: Very nice Greg. Well, the next paper is actually one we've already discussed in our special COVID-19 edition and that was aired on 22nd, May, 2020. That's the paper from Dr Poissy and Susen from University Lille in Inserm, and they reported a case-series of COVID-19 patients with pulmonary embolism in their institution of Lille University Hospital. So, please everybody remembers to tune in to that as a refresher. Also in today's journal, the issue of COVID-19 coagulopathy in venous thromboembolism is further discussed in an editorial by Dr Alex Spyropoulos and Dr Jeffrey Weitz. Let me tell you a bit more about other papers in this week's issue. There are letters to the editor from Dr Mueller and from Dr Gulati all about the paper incidents, trends and outcomes of type two myocardial infarction in the community cohort. There's a letter from Dr Siontis on the blood pressure myocardial infarction paradox. Dr Carolyn Lam: Does hypertension exert a protective effect in type two MI? In the ECG challenge Dr Di Cosola talks about the high, the low end, the narrow QRS in a peripartum cardiomyopathy. There's an online mind piece by Dr Kohli entitled surfing the waves of the COVID-19 pandemic as a cardiovascular clinician, a perspective piece by Dr Albert titled "The Heart of the Matter Unmasking and Addressing COVID-19's Toll on Diverse Populations". In Paths the Discovery series, Dr Rutherford talks about serial innovation to bring transformative precision medicines to people with serious diseases. And this is a conversation with Dr Jeffrey Leiden. Dr Greg Hundley: Very nice. Carolyn, I've got a couple other papers to discuss similar to your paper on DVT, Professor Lin Cai has a research letter involving the extremely high incidents of lower extremity, deep venous thrombosis in 48 patients with severe COVID-19 from Wuhan China. In an on my mind piece, Dr Anum Saeed from University of Pittsburgh discusses reinforcing cardiology training during a pandemic. It's an open letter to our leaders. Our own Bridget Kuhn has a piece entitled COVID-19 leads to major changes for cardiologists in training. And then finally, Dr Stephen Archer from Queens University provides a nice perspective on differentiating COVID-19 pneumonia from ARDS and high-altitude pulmonary edema, and what are the therapeutic implications. And now Carolyn, how about we get onto that feature discussion, one of the unusual times where we emphasize an important point in a research letter? Dr Carolyn Lam: You bet, Greg. Today's feature discussion is I think one of the most impactful, basic science papers we have, and that is why we're discussing it. I am so pleased to have the first author Dr Luca Liberale from University of Zurich, as well as Dr Peipei Ping associate editor from UCLA. So welcome both. Luca, I really need your help here. Can you please explain what your experiment was and your main findings? Dr Luca Liberale: We really happy that we could set up an experiment design, which has some kind of translation of value. So, differently from any other set up involving the tandem middle cerebral artery occlusion, which is among the most used model for ischemic stroke in basic science. In this case, the treatment is done post-ishchemically. So the mice received the neutralizing antibody against IL-1α only after they scan making salts. And we specifically thought to duties to keep the translational relevant side. As I said before, and trying to mirror the case of a patient, we think come have a stroke that goes to the emergency department, and he is eligible for revascularization therapy. And together with this revascularization therapy being at EPA or whatever for it, it received is also the kind of anti-IL-1α treatment. And another good translation of relevancy we thought this may have is that identifying of IL-1α antibody is already available in the market and being in many phase three trial. So we thought this is a ready to go, ready for the translation from the bench to the bedside, as we used to say. Dr Carolyn Lam: It's just so interesting because when we think about ischemic stroke, you know, we think about thrombolysis as practically the only thing we can do, and forgive me I'm not in neurologist here, but this is so unique to go with an anti-inflammatory mechanism. Now, when you see that this neutralizing antibody is currently in use, do you mean in cancer in other diseases? Dr Luca Liberale: Mainly it's cancer, but it's also other dermatological diseases. It's not only cancer, but oh yes, definitely. Cancer is one of the major fields of its application. Dr Carolyn Lam: Wow. So with that very interesting background, could you tell us about the experiment and what you found? Dr Luca Liberale: What we found is that after inducing ischemia in the animal for 45 minutes, we let them reperfuse for 48 hours during which the animal are under the treatment. So they received a bolus of anti-IL-1α immediately at the time of reperfusion. So when we take out from the carotid artery, the filament, and they received these volumes and they are let survive for 48 hours. So they are free to go in the cage, to seek drinks. After 48 hours, we assessed the neurological deficit and we sacrifice the animal to assess the stroke size by using the quite common PTC staining. And what we could find is that indeed the treatment with the higher dose, because we use two doses, and we could see a dose response, could that reduce the stroke size by 36% as compared to the treatment with the isotype control. And this went together with a significant reduction in that neurological impairment. So it's not only an experimental reduction, but it's also physiologically relevant for the animals. Dr Carolyn Lam: That really is incredible, and the way you manage to convey such a lot of data in a research letters is also remarkable. So, to the audience, you have to pick this up. It's a succinct read, just this one central figure that tells the whole story, and you're about to hear from Dr Ping. Dear Peipei, if you could tell us what the significance of this paper is, maybe some of the discussions that occurred behind the doors, so to speak among the editors.   Dr Peipei Ping: We were super impressed with the fundamental message of the submitted report. Carolyn, as you are fully aware, most ischemic studies speed that in the heart or in a brain model, often select mechanisms that must be activated pre the event you bent of ischemia to induce a protective effect, a neurological protective effect in stroke or cardioprotective effect in the heart. So, as an associate editor who spent her entire 30 years career in this area of study, we often fascinated about the sentencing or the naiveness of the basic scientists in this area. Because you would have to plan an ischemia in the patient knowing when that to happen. And then before that happens, activate all these beautiful signaling and mechanisms, everything you have generated to prevent that ischemia. So the search for the possible mechanistic understanding of a post-ischemic event rescue mechanism has been going on for decades. And it's very, very challenging, Carolyn. Dr Peipei Ping: The beauty of the study is it utilized already in clinical trial, existing human antibody inhibitor, interleukin alpha-one antibody. You said antibody. So the reagent is already bile approved. Then examine very carefully in a post-ischemic fashion to see how relevant that agent in a time window reasonable to rescue ischemic injury. You can already tell from Lucas introduction; the results are profound, and it has stimulated many discussions in the field. It's very relevant to clinical center piece, even though it's still at that translational stage. So we saw this as a beautiful representation of how clinicians and scientists capable of not only bring something from the bench to the clinic or the clinic or to the bench. This is something comes to a full circle. It went from clinic where the reagent was used and created for something to the bench, understanding mechanistic insight, have a beautiful animal of human disease stroke model to test them and then take it to the clinic again. Dr Carolyn Lam: Goodness, Peipei. I love the way you put that. I actually didn't see that Luc[a], till you put it that way. I do have a couple of questions for Luca though. I understand you made it very clear in your paper that the human monoclonal antibody is in clinical use, but in this experiment, you had to use the rodent equivalent because the human antibody doesn't block the rodent IL-1α, which is very reasonable. But then it brings the question, how closely does this rodent model recapitulate thrombotic ischemic, or a stroke in humans? I mean, what do you think? Dr Luca Liberale: Well, what we see when we use our usual approach, this is a model that we're using in our center for molecular cardiology here in Zurich, and this been used in that specific group of Professor Ameche for many years. And this is usually quite well accepted as a model. So that, that the timeframe is 45 minutes of ischemia and 48 hours of reperfusion. I'll got to quite mirror the acute phase of an acute ischemic stroke, which is actually where we think that the inflammatory pathways can play the major roles. Also. I mean, everybody of us know that the recent anti-inflammatory trials confirmed this, that reducing the inflammation and the inflammatory pathways is good but can also be harmful. Dr Luca Liberale: So in the case, we can use an approach, which is limited in the time, maybe really close to that acute phase, really during the acute rates goes to the acute event. Well, maybe this can be quite useful and quite a translationally relevant that prolongs inactivation of such pathways as result. They can ask some for, so the balance in between the benefits and the harms cannot be that clear, can, I mean, needs to be quite well addressed. Dr Carolyn Lam: And that actually brings me to the next question. You know, the word translational has been mentioned quite a number of times here. So can you give us a sneak-peak on what the translational plans that your team may have? What's the next steps? Dr Luca Liberale: The next steps now is back to the company. So our basic findings are here. They will be published soon, and now it's all about the clinical scientist, and how they want to implement these basic findings into the clinic. Dr Carolyn Lam: So target engagement and mechanistic information as well. Peipei, could I just give you the last word, if you don't mind, maybe a bit of a cheeky question. What would you have loved to see in this paper or in a subsequent paper that offers a step closer to translation? Dr Peipei Ping: I think this study has shown most necessary components as a basic science research paper. I think the next level closer to the translation as Luca has already alluded to, has to do with both efficacy studies, as well as safety studies, and those actually would need to be done in the clinic because the mouse model. I think it's a fantastic model to offer these lines of information. Ischemic-wise I think it's very strong and translational value is very high and that was the predominant reason we voted to accept the paper. As you know, the accept and raise of circulation is very, very low as our bar is very high. Dr Carolyn Lam:  Very nice. So target engagement and mechanistic information as well. Congratulations, Luca. Thank you so much Peipei for your great comments. Now, listeners, you heard it first time here on Circulation on the Run. Thank you for joining us today.  Dr Greg Hundley: This program is copyright at the American Heart Association, 2020.  

The global movement Plastic Free July begins today.Millions take part to see if they can reduce single use plastic use for a month - a task easier said than done.However, it may not be all that hard. For the last two years, one Auckland family with five children has thrown out one bag of rubbish each year - and they'll have some good tips on where to start.Father Stephen Archer joined Kate Hawkesby to discuss how they pulled it off.LISTEN ABOVE 

Munster Forwards Coach Graham Rowntree and Stephen Archer, who is set to make his 200th appearance, look ahead to Friday night’s clash against Edinburgh at Irish Independent Park (7.35pm).

In this podcast I am thrilled to share my chat with my mindfulness mentor, Stephen Archer. Stephen is the Director and Lead Trainer and Supervisor for Mindfulness Works for Organisations. To find out more about Stephen you can visit his website at https://mindfulness-training.co.nz/. Find out more about Mindfulness Works at https://mindfulnessworksaustralia.com.au/an-introduction-to-mindfulness-and-meditation-adelaide/#1558669035498-b23dc5b1-435e. And find out more about Te Moata and Stephen's retreats at http://temoata.org/te-moata/.

My guest this week is business analyst, consultant and former Trustee and Communications Director for the Cutty Sark, Stephen Archer. Stephen talks about leadership in the context of the changes in European and global economics and the shifts in the political impetus behind globalisation.  He is both excited and vexed by what is going on.  His work is focused on supporting leaders to navigate through the chaos of what may seem impossibly unpredictable times.  In this week’s show, we talk about making sense of the chaos of what is going on in world and we hear about the 5 traits that make a great leader. Bio Stephen Archer’s expertise and experience uniquely places him to speak on the changes in worldwide economics and structural changes and their impact on your organisation. The ‘new order’ of globalisation is now being rocked, free trade is no longer a given and even democracy cannot be taken for granted.  In short, we have entered a period of instability. All of these fundamental 21st century changes are happening so fast that the need for a special kind of leadership is now essential. For everyone it is increasingly hard to see through the fog of news and decipher the implications. Employees and customers alike feel the same and look for informed leadership to help them to understand the place of the organisation and the individual in today’s world. Issues such as runaway global debt, trade wars, populism, nationalism, low economic growth rates, artificial intelligence and volatile sovereign leadership are all taking their toll on confidence and despite ‘progress’ there is also a widespread retrenchment in investment. This is understandable with such uncertainty, but an understanding of more certainty is possible. Stephen will take you through the state of the planet today and how all of these pieces fit together. He will lay out a clear picture of what is happening and how to lead yourself and your organisation through the coming years. It’s a serious topic but Stephen is an entertaining man – you will have fun on the journey. As he says: “I refuse to get depressed by world events. There is so much craziness going on and feral behaviour amongst politicians. You can turn off the news in horror, but I prefer to understand it and see the absurdities and the funny side. If you see the funny side it helps to make sense of it all and give a clearer perspective.” Stephen Archer has been a consultant to multi-national companies in the USA and Europe at C-suite level. His main areas of expertise are commercial performance and leadership improvement in high-performance organisations. Stephen talks both in the capacity of an advisor to businesses and from the perspective of a business owner and someone who has set up and sold businesses. A decade ago he became a regular commentator on the challenges of the world’s politico-economic flux. In this time of unprecedented uncertainty he brings clarity to issues surrounding Brexit, global leadership and the economic outlook. He was a Trustee and then chairman of Cutty Sark when it went through the disastrous fire and rebuild but was there for the Queen to re-open it in 2012.  Recorded: 8th November 2018 Links: More about Stephen Archer More about Maria Franzoni Ltd Connect with Maria on Linkedin Connect with Maria on FaceBook  To book any of the speakers featured on the Speaking Business podcast, click here  

Stephen Archer tells the story of Aston Martin Ulster CMC 314. one of 28 Ulsters built by the company and the most raced Aston Martin. It has been restored to 1935 Le Mans spec. In addition to this Ulster, Stephen also describes Aston Martin's first 20 years in general. A fascinating account delivered with some exuberance and panache!

Dr Carolyn Lam:                Welcome to Circulation On The Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore.                                                 This week's journal features two papers. One a research letter and the second an original article, both focusing on the effect of ionizing radiation on interventional cardiologists. I'm sure that cuts close to the heart, so please stay tuned. Coming up right after these summaries.                                                 The first two original articles in this week's journal describe a metabolic adaptation that is good for the abnormal cell but bad for the patient. This is a shift in glucose metabolism called the Warburg phenomenon where there is failure of two fundamental pathways. Number one glucose metabolism and number two mitochondrial oxygen sensing. This Warburg phenomenon enables a reliance on glycolysis despite an abundance of available oxygen. These two circulation articles uncover new players in the Warburg phenomenon, both in the setting of pulmonary arterial hypertension. One in the pulmonary arterial endothelial cells, and the second in fibroblasts.                                                 In the first paper, first and corresponding author Dr. Caruso and co-corresponding author Dr. Morrell from the University of Cambridge examined the microRNA and proteomic profiles of blood outgrowth endothelial cells from patients with heritable pulmonary arterial hypertension due to mutations in the bone morphogenetic protein receptor type two, or BMPR2 gene, and in patients with idiopathic pulmonary arterial hypertension. They demonstrated that reduced expression of microRNA-124 in pulmonary arterial hypertension endothelial cells was responsible for the dysregulation of the splicing factor polypyrimidine tract binding protein 1, and its target pyruvate kinase M2 or PKM2, which is a major regulator of glycolysis and which contributes to abnormal cell proliferation. Reduced BMPR2 levels were associated with reduced microRNA-124 expression.                                                 In the second paper first author Dr. Zhang, corresponding author Dr Stenmark and colleagues from the University of Colorado studied pulmonary adventitial fibroblasts isolated from cows and humans with severe pulmonary hypertension. PKM2 inhibition reversed the glycolytic status of pulmonary hypertension fibroblasts, decreased their cell proliferation and attenuated macrophage interleukin beta expression.                                                 Normalizing the PKM2 to M1 ratio in pulmonary hypertension fibroblasts by using microRNA-124 over expression, or by PTBP1 knockdown, reversed the glycolytic phenotype, rescued mitochondrial reprogramming and decreased cell proliferation. Finally, pharmacological manipulation of PKM2 activity or treatment with histone deacetylase inhibitors produced similar results. These findings provide new avenues for the treatment of pulmonary arterial hypertension and are discussed in an accompanying editorial by Stephen Archer from Queen's University in Ontario Canada.                                                 The next paper tells us that the addition of ezetimibe to simvastatin in patients stabilized after acute coronary syndrome reduces the frequency of ischemic stroke, with a particularly large effect seen in patients with a prior stroke. First and corresponding author Dr. Bohula and colleagues from the TIMI study group investigated the efficacy of the addition of ezetimibe to simvastatin for prevention of stroke in the IMPROVE-IT trial where post ACS patients were randomized to placebo and simvastatin or ezetimibe and simvastatin and followed for a median of six years.                                                 The current study focused on patients with a history of stroke prior to randomization. The authors found that the addition of ezetimibe to simvastatin reduced the frequency of ischemic stroke with a hazards ratio of 0.79, with a particularly large effect seen in patients with a prior stroke, where the hazards ratio was 0.52, compared to patients without a prior stroke where the hazards ratio was 0.84. Hemorrhagic strokes were rare and a non significant increase in hemorrhagic stroke was observed with the addition of ezetimibe. Thus, the authors concluded that it is reasonable to consider the addition of ezetimibe, a generic lipid lowering therapy with an acceptable safety profile, to a moderate to high intensity statin regimen for the prevention of ischemic stroke in patients with established ischemic heart disease, with or without a prior stroke.                                                 Atrial fibrillation is the most common sustained arrhythmia in hypertrophic cardiomyopathy, but the influence of atrial fibrillation on clinical course and outcomes in hypertrophic cardiomyopathy had remained incompletely resolved. That is until today's paper in circulation. First and corresponding author Dr. Rowin and colleagues from Tufts Medical Center accessed the records of 1,558 consecutive patients followed at the Tufts Medical Center hypertrophic cardiomyopathy institute for an average of 4.8 years from 2004 to 2014.                                                 20% of patients had episodes of atrial fibrillation, of which 74% were confined to symptomatic paroxysmal atrial fibrillation, while 26% developed permanent atrial fibrillation. They found that the timing and frequency of paroxysmal atrial fibrillation events were unpredictable with an average two year interval between the first and second symptomatic episodes but progressing to permanent atrial fibrillation uncommonly. They further found that atrial fibrillation was not a major contributor to heart failure morbidity, nor a cause of arrhythmic sudden death, and when atrial fibrillation was treated it was associated with low disease related mortality, no different than for patients without atrial fibrillation. Finally, atrial fibrillation was an uncommon primary cause of death in hypertrophic cardiomyopathy, but this was virtually limited to embolic stroke, thus supporting a low threshold for initiating anticoagulation therapy.                                                 That warps it up for our summaries. Now for our feature discussion. This week's journal carries two papers that refer to the health risks of ionizing radiation to interventional cardiologists. Yes, you heard me right. You're going to want to listen up. These are going to send chills up our spine, or rather maybe chills into our brains and into our blood according to the papers.                                                 To discuss these two papers I have with us associate editor from UT Southwestern, Dr. Manos Brilakis, as well as the corresponding author of the first paper Dr. Maria Andreassi from CNR Institute of Clinical Physiology from Pisa Italy. Maria, could you start us off by telling us what you found in your research letter? Dr Maria Andreassi:        In our study we evaluated the circulating microRNA profile in interventional cardiologists in order to provide insights into the molecular and the biological situation and the underlying association between occupational low dose radiation exposure in cath lab and the potential long term disease risk. The hypothesis of our study was based on the evidence that the microRNAs are crucial regulators of gene expression. And they have been shown to be dysregulated in many human disease. Moreover, the stability and the tissue selectivity of circulating microRNAs make them ideal biomarkers to explore disease potential clinical disease risk.                                                 In summary, our findings exhibited the dysregulation and the down regulation of acute specific circulating microRNA, the brain specific microRNA-154 and the microRNA-2392. This tells us significantly involved in the deregulation of the three brain pathways and the brain cancer pathway as demonstrated by systematic analysis. In particular, the dysregulated labels so the brain specific microRNA-154 in interventional cardiologists support the notion that the brain damage is one of the main potential long term risk on unprotected head radiation in interventional cardiologists with possible long lasting consequences on the cognitive function. Dr Carolyn Lam:                That is really striking. Brain specific microRNA was shown to be dysregulated in interventional cardiologists compared to controls who were not exposed to radiation. As I understand it, these dysregulated microRNAs can be seen in certain forms of epilepsy and Alzheimer's disease and certain brain cancers and so the concern is very obvious for those of us who are interventional cardiologists. But your study did not actually relate these two specific adverse events. Is that correct? Dr Maria Andreassi:        You're right. Yes. microRNA-154 was first identified as a brain specific microRNA which is involved with inner synapse development and the directly implicated in [inaudible 00:12:15] and memory. Additionally, decreased expression of this microRNA class, was previously reported in several brain disorders including the thymus disease and bipolar disorder. This microRNA has also been shown to be down regulated in several brain cancers such as neuroblastomas. The reduced expression of the microRNA-154 is a predictor of progression and prognosis of human gliomas. This data strongly support it's important role in brain tumors. Our findings are of particular interest in relation the handle exposure to the pathology of the head, the [inaudible 00:13:13] 20, 50 millisieverts. The equivalent to 1,000, 2,000 chest x-rays and can reach a lifetime cumulative exposure around two sieverts for left hippocampus and one sievert for right hippocampus. Dr Carolyn Lam:                That really makes me go, yikes. But Manos, as an interventional cardiologist yourself, what are your thoughts? And also your thoughts please on that other paper that's in this week's journal? Dr Manos Brilakis:            First of all, let me just congratulate Maria Andreassi, she's been one of the leaders in this area and published several papers and this is one of them. It's really important to have these studies because unfortunately we as interventional cardiologists tend to forget about the negative affects of radiation because as you hear, people don't really see them and this can happen many years down the line. And by the time they happen, it's too late. It's really useful to have the studies to bring our attention the importance of keeping the radiation exposure to the patient and to ourselves as low as possible.                                                 The other paper in addition to the one just discussed, is a paper that looks at DNA damage on operators performing endovascular aortic repair. As a preface, these are procedures demonstrated the aortic aneurism repairs which are very intense radiation wise. They are long procedures, fielding can sometimes be challenging for the operator. There is significant exposure of the operator to x-ray. What they did is they measured some markers of DNA damage and repair. Specifically gamma-H1AX and DDR, the DNA damage response marker and the pATM. They measured them in circulating lymphocytes in operators who performed the endovascular aortic aneurism. What they found is that there were significantly higher levels of those markers immediately after those operators performed those procedures. And they did the same thing after x-ray using leg shielding.                                                 That's a very good reminder for us that the x-ray tube actually is not on the top of the table, but the x-ray tube, the generator, of the x-rays is actually on the bottom. Then the x-ray goes through the patient and the detector is at the top of the table and what happens is the x-ray comes from below the patient and gets scattered from the patient and coming towards the operator so actually it's the legs get the higher dose during any sort of x-ray guided procedure. Sometimes we're forgetting importance of shielding the legs 'cause we think the legs, whatever the muscles, the bones, they're fine. But as the study shows, it's not just the muscles and the bones there but the whole circulation blood gets exposed to x-ray in the lower extremity circulation and that can translate to many other potentially adverse events. Dr Carolyn Lam:                Manos, I love that you manage both these papers. What important messages for increase in risk awareness. This was really very, very well accomplished by both these papers. As well by the editorial that you asked for and that was so well written by Dr. Charles Chambers on both these papers. But beyond risk awareness, what I really love is what you brought up just a while earlier about risk reduction and methods that we can take, for example, in the second paper, by Dr. Modoari and colleagues about shielding the legs. What are the implications for example, wearing a helmet or shielding the head for interventional cardiologists? What do you think? Dr Manos Brilakis:            These are very, very good points. The reality is for the head there have been a couple studied that looked at shielding with lead caps or there's some lead free caps that can be worn and also there are radiation protective glasses. However, what was interesting, there was a paper earlier last year that showed that because the radiation actually comes from below the operator that wearing those helmets, although it seems appealing, it is simple to do obviously, it actually did not significantly reduce the dose to the brain and it only partially reduced the dose to the eyes. Though shielding is useful but may not be as good as we think it is.                                                 In my mind, the starting point of all this is the basics of radiation safety which again, sound very simple and we learn about them in the beginning of training, unfortunately what happen is people tend to forget them as time goes by. These are things like don't step on the x-ray pedal unless you need to look at the pictures and that's very common done. People just have this heavy foot syndrome. They keep on x-raying when they don't need to. There's also the important things having the patient as high as possible and the detector as close to the patient so there is not as much distance for the x-ray to travel. Things like using low, not very steep angles so there is not as much radiation because they have to go through less amount of tissue. And there's some technologies actually coming along there's some technologies that focus the radiation beam only specific areas. And cut the overall dose. And there are x-ray machines that also can have much less radiation overall for the patient and the operator. As you said, having good shielding habits is very important. Dr Carolyn Lam:                Yeah, that's exactly it. That risk awareness should lead to action. I'm just curious, who do you think should primarily take hold of these risk reduction and safety procedures and the enforcement and so on? Us as a community, but what do you think of the role of things like professional societies, quality improvement programs, FDA even? Dr Manos Brilakis:            It's a great point. What we hear here Maria's comments on this as well. But my feeling is absolutely societies are very important for leading these efforts and they do have actually guidelines. There's procedural guidelines for radiation protection. But the end of the day it's the individuals themselves, the operators, each and every one who is in charge of this in their care or his own cath lab and their procedures. Dr Maria Andreassi:        I agree. We all of our findings can contribute to the increase of cross cultural assessment in cath lab and by promoting the diffusion but not the reduction technologies whereas diligent about your protection habits. Moreover it is important to let the design, the relationship between occupational radiation exposure, clinical risk and there are very important future studies studying larger population. We should focus on the molecular epidemiology studies by using biomarkers and this will be clinical and points as early predictors of a clinical event. Because this information is a model likely to better define the risk of radiation use disease at low doses as a comparative tool, the classical epidemiological approach that require a very large sample sizes spread over [inaudible 00:20:51].                                                 Now it's time where largest studies involving scientific societies at an international level. Possible breaking the additional exposure in already recruited the Roth case. And by combining the conventional epidemiology, and the molecular studies and the expected results to better define the clinical risk as a good lesson to implement a more effective protection program. And better as the surveillance at the individual level. Dr Carolyn Lam:                That is wonderful. And thank you, this truly is an international call, isn't it? Another thing that we should keep in mind that all measures that we use to protect our patient from receiving excessive radiation is likely to help us as well as cardiologists.                                                 Thank you so much, both of you, for joining me today on this podcast. What an important message and I'm sure that our listeners will agree. Thank you listeners for joining us. Tune in again next week.  

Nick Candee is the Vice Chair and Historian of the Aston Martin Owner’s Club East serving eastern Canada and the US. He is the former editor of The Vantage Point magazine, an Aston Martin Club publication and he is the Principal of Candee & Company with over 30 years of expertise in international corporate planning, specializing in Latin American markets. Nick just published a new book, co-authored with Stephen Archer titled The Aston Martin DB4GT published by Palawan Press in the United Kingdom. This 544 page book with over 800 photographs and illustrations examines in detail the history of every DB4GT manufactured including the design and development of the car. It is a definitive collectors book telling the brilliance and craftsmanship required to build these magnificent cars.